KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Work In Process (2022 - 2025)

Sarepta Therapeutics has reported Work In Process over the past 4 years, most recently at $892.7 million for Q4 2025.

  • For Q4 2025, Work In Process rose 46.18% year-over-year to $892.7 million; the TTM value through Dec 2025 reached $892.7 million, up 46.18%, while the annual FY2025 figure was $892.7 million, 46.18% up from the prior year.
  • Work In Process for Q4 2025 was $892.7 million at Sarepta Therapeutics, up from $885.4 million in the prior quarter.
  • Over five years, Work In Process peaked at $892.7 million in Q4 2025 and troughed at $269.2 million in Q4 2022.
  • A 4-year average of $610.5 million and a median of $610.7 million in 2024 define the central range for Work In Process.
  • Biggest five-year swings in Work In Process: rose 18.3% in 2023 and later surged 91.77% in 2024.
  • Year by year, Work In Process stood at $269.2 million in 2022, then grew by 18.3% to $318.5 million in 2023, then surged by 91.77% to $610.7 million in 2024, then skyrocketed by 46.18% to $892.7 million in 2025.
  • Business Quant data shows Work In Process for SRPT at $892.7 million in Q4 2025, $885.4 million in Q3 2025, and $802.9 million in Q2 2025.